G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
– Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA (trilaciclib) –
– Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication of Permanent J-Code for COSELA –
– Initiation of…
